No Result
View All Result
  • Private Data
  • Membership options
  • Login
  • COUNTRY
    • ITALY
    • IBERIA
    • FRANCE
    • UK&IRELAND
    • BENELUX
    • DACH
    • SCANDINAVIA&BALTICS
  • PRIVATE EQUITY
  • VENTURE CAPITAL
  • PRIVATE DEBT
  • DISTRESSED ASSETS
  • REAL ESTATE
  • FINTECH
  • GREEN
  • PREMIUM
    • ItaHubHOT
      • ItaHub Legal
      • ItaHub Tax
      • ItaHub Trend
    • REPORT
    • INSIGHT VIEW
    • Private Data
Subscribe
  • COUNTRY
    • ITALY
    • IBERIA
    • FRANCE
    • UK&IRELAND
    • BENELUX
    • DACH
    • SCANDINAVIA&BALTICS
  • PRIVATE EQUITY
  • VENTURE CAPITAL
  • PRIVATE DEBT
  • DISTRESSED ASSETS
  • REAL ESTATE
  • FINTECH
  • GREEN
  • PREMIUM
    • ItaHubHOT
      • ItaHub Legal
      • ItaHub Tax
      • ItaHub Trend
    • REPORT
    • INSIGHT VIEW
    • Private Data
Home COUNTRY SCANDINAVIA&BALTICS

SciBase continues US expansion and will attend Fall Clinical conference

Cisionby Cision
October 21, 2024
Reading Time: 4 mins read
in SCANDINAVIA&BALTICS, VENTURE CAPITAL
Share on FacebookShare on Twitter

STOCKHOLM, Oct. 21, 2024 /PRNewswire/ — SciBase Holding AB (“SciBase”) (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders will attend a leading US dermatology conference, Fall Clinical, to further enhance the clinical adoption and market expansion of Nevisense. The Fall Clinical conference attracts more than 1,100 clinicians looking to bridge gaps within the detection and diagnosis of melanoma clinical pathway. The conference offers comprehensive workshops and sessions led by top dermatology experts highlighting the latest advances in the diagnoses and treatment of various conditions and diseases. Nevisense will be included in several sessions focused on integrating technology into the melanoma detection and diagnostic clinical pathway.

SciBase continues to expand geographically in the US with new practices added in Maryland, Colorado and as recently published Pennsylvania. The Fall Clinical conference will provide an opportunity to further extend the US footprint and provide new customers with Nevisense. Nevisense is today the only FDA approved, non-invasive option for the detection of melanoma at an early stage when the disease is highly curable.

The new consensus report that was published in the JDD (September 2024 issue) will also be presented at the 44th annual Fall Clinical Dermatology Conference (“Fall Clinical 2024”).  The consensus report evaluated several technologies for melanoma diagnosis and supports the use of Nevisense for its ability to significantly enhance clinician’s diagnostic assessment of atypical moles by non-invasively providing them with critical information at point of care. 

“It is very encouraging to see that our recently added resources already are expanding our geographical footprint in the US, and we have recently opened up new markets in Pennsylvania, Maryland and Colorado. We are excited to continue this momentum during the Fall Clinical 2024 conference. SciBase is proud to support and attend the Fall Clinical 2024 conference and we look forward to engaging with our current customers as well as establishing new customers to further our mission of providing both clinicians and patients with improved outcomes and to positively impact the betterment of patient care.,” said Pia Renaudin, CEO of SciBase.

For additional information, please contact:
Pia Renaudin, CEO, tel. +46732069802, e-mail: pia.renaudin@scibase.com

Certified Advisor (CA):
Carnegie Investment Bank AB (publ)
Phone: +46 (0)73 856 42 65
E-mail: certifiedadviser@carnegie.se

About SciBase

SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management.

Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.

Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.

The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company’s Certified Adviser is Carnegie Investment Bank AB (publ).  Learn more at www.scibase.com. For press releases and financial reports visit: http://investors.scibase.se/en/pressreleases 

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/scibase/r/scibase-continues-us-expansion-and-will-attend-fall-clinical-conference,c4053734

The following files are available for download:

https://mb.cision.com/Main/12371/4053734/3063312.pdf

FC24 PR

 

Cision View original content:https://www.prnewswire.co.uk/news-releases/scibase-continues-us-expansion-and-will-attend-fall-clinical-conference-302281470.html

Read the orginal article: undefined

Gateways to Italy

Gateways to Italy – Offer your services to funds and investors willing to explore opportunities in Italy. Become a partner!

Gateways to Italy – Offer your services to funds and investors willing to explore opportunities in Italy. Become a partner!

by Partner
June 6, 2023

Sign up to our newsletter

SIGN UP

Related Posts

FINTECH

Qonto power players: the leadership team behind the French fintech unicorn

May 9, 2025
DACH

German FinTech startup Circula secures €15 million as it cuts expense admin by 80%

May 8, 2025
FRANCE

EU unlocks €500m to become a “magnet for researchers”

May 8, 2025

ItaHub

Crypto-assets supervision rules in Italy, Banca d’Italia will supervise payment systems and Consob on market abuse

Crypto-assets supervision rules in Italy, Banca d’Italia will supervise payment systems and Consob on market abuse

November 4, 2024
Italy’s SMEs export toward 260 bn euros in 2025

Italy’s SMEs export toward 260 bn euros in 2025

September 9, 2024
With two months to go before the NPL Directive, in Italy the securitization rebus is still to be unraveled

With two months to go before the NPL Directive, in Italy the securitization rebus is still to be unraveled

April 23, 2024
EU’s AI Act, like previous rules on technology,  looks more defensive than investment-oriented

EU’s AI Act, like previous rules on technology, looks more defensive than investment-oriented

January 9, 2024

Co-sponsor

Premium

Funds vying for management consulting firm BIP, a CVC portfolio company. All deals in the sector

Funds vying for management consulting firm BIP, a CVC portfolio company. All deals in the sector

March 6, 2025
Private equity, Italy 2024 closes with 588 deals as for investments and divestments from 549 in 2023. Here is the new BeBeez’s report

Private equity, Italy 2024 closes with 588 deals as for investments and divestments from 549 in 2023. Here is the new BeBeez’s report

February 10, 2025
Crypto-assets supervision rules in Italy, Banca d’Italia will supervise payment systems and Consob on market abuse

Crypto-assets supervision rules in Italy, Banca d’Italia will supervise payment systems and Consob on market abuse

November 4, 2024
Venture capital investments top €1.3bn in 208 rounds as of Sep30  in Italy. They were €1.5 in all 2023. The new BeBeez Report

Venture capital investments top €1.3bn in 208 rounds as of Sep30 in Italy. They were €1.5 in all 2023. The new BeBeez Report

October 28, 2024
Next Post
Private equity, returns recovering slightly after lean times. All the numbers compared

Private equity, returns recovering slightly after lean times. All the numbers compared

FRESHA INVESTS IN YUV TO REVOLUTIONIZE HAIR COLORING WITH CUTTING-EDGE TECHNOLOGY

EdiBeez srl

C.so Italia 22 - 20122 - Milano
C.F. | P.IVA 09375120962
Aut. Trib. Milano n. 102
del 3 aprile 2013

COUNTRY

Italy
Iberia
France
UK&Ireland
Benelux
DACH
Scandinavia&Baltics

CATEGORY

Private Equity
Venture Capital
Private Debt
Distressed Assets
Real Estate
Fintech
Green

PREMIUM

ItaHUB
Legal
Tax
Trend
Report
Insight view

WHO WE ARE

About Us
Media Partnerships
Contact

INFORMATION

Privacy Policy
Terms&Conditions
Cookie Police

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • COUNTRY
    • ITALY
    • IBERIA
    • FRANCE
    • UK&IRELAND
    • BENELUX
    • DACH
    • SCANDINAVIA&BALTICS
  • PRIVATE EQUITY
  • VENTURE CAPITAL
  • PRIVATE DEBT
  • DISTRESSED ASSETS
  • REAL ESTATE
  • FINTECH
  • GREEN
  • PREMIUM
    • ItaHub
      • ItaHub Legal
      • ItaHub Tax
      • ItaHub Trend
    • REPORT
    • INSIGHT VIEW
    • Private Data
Subscribe
  • Login
  • Cart